Kezar Life Sciences shares are trading lower after the company reported a year-over-year decrease in Q2 EPS results. Also, Wells Fargo downgraded the stock from Overweight to Equal-Weight, while HC Wainwright lowered its price target from $19 to $18 on the stock.
Portfolio Pulse from Benzinga Newsdesk
Kezar Life Sciences reported a year-over-year decrease in Q2 EPS results, leading to a drop in its share price. Additionally, Wells Fargo downgraded the stock from Overweight to Equal-Weight, and HC Wainwright lowered its price target from $19 to $18.
August 11, 2023 | 2:31 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Kezar Life Sciences' stock is expected to face downward pressure due to poor Q2 EPS results and negative analyst ratings.
Kezar Life Sciences reported a decrease in Q2 EPS results, which is a negative signal for investors. Additionally, the stock was downgraded by Wells Fargo and had its price target lowered by HC Wainwright, further indicating a negative outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100